Study Overview: This study is testing a medicine called lunsekimig to see if it helps adults with asthma. Asthma is a condition that makes it hard to breathe because airways in the lungs get narrow. Participants will be randomly chosen to receive either the medicine or a placebo (a fake treatment that looks like the medicine) as an add-on to their current treatment. This is a double-blind study, meaning neither the participants nor the researchers know who is getting the real medicine. It will help us understand if lunsekimig is safe and works well for people with moderate-to-severe asthma.

• Duration: The study lasts for at least 12 months.
• Visits: Participants will need to visit the study center multiple times.
• Compensation: Participants may receive compensation for their time.

Eligibility: Adults aged 18-80 with moderate-to-severe asthma for at least a year, who have had at least one severe asthma attack in the past year, are eligible. People with other serious lung diseases, recent smoking history, or recent serious infections cannot join.